Document is current
Any future updates will be listed below
-
Authors
Fujimura, Yota https://orcid.org/0000-0001-5961-7249
Shimura, Akiyoshi
Morishita, Chihiro
Tamada, Yu
Tanabe, Hajime
Kusumi, Ichiro
Inoue, Takeshi
-
Funding
Funding for this research was provided by:
a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (no. 16 K10194)
Research and Development Grant for Comprehensive Research for Persons with Disabilities from Japan Agency for Medical Research and Development
a grant from SENSHIN Medical Research Foundation
- License Information
-
More Information
Article History
Received: 22 January 2023
Accepted: 7 July 2023
First Online: 24 July 2023
Declarations
:
: Ethics approval was obtained from the Institutional Review Boards of Hokkaido University Hospital and Tokyo Medical University (study approval no. 013–0184 and SH3308, respectively).
: Written informed consent was obtained from all participants prior to their enrollment in the study.
: Yota Fujimura has received honoraria from Sumitomo Pharma and research and grant support from Otsuka Pharmaceutical, Sumitomo Pharma, and Shionogi. Akiyoshi Shimura has received lecture fees from Sumitomo Pharma and Eisai. Yu Tamada has received honoraria from Otsuka Pharmaceutical, Sumitomo Pharma, Eisai, MSD, and Meiji Seika Pharma. Ichiro Kusumi has received honoraria from Eisai, Eli Lilly, Janssen Pharmaceutical, Meiji Seika Pharma, Mochida Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, Viatris, and Yoshitomiyakuhin and has received research/grant support from Asahi Kasei Pharma, Astellas, Daiichi Sankyo, Eisai, Eli Lilly, Mochida Pharmaceutical, Nihon Medi-Physics, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, and Tanabe Mitsubishi Pharma. Takeshi Inoue is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma and has received personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai and grants and personal fees from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma. The other authors declare that they have no actual or potential conflicts of interest associated with this study.
